Business
Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares
Dublin, Ireland--(Newsfile Corp. - February 3, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the successful completion of a private placement of 937,086 treasury shares. The shares were placed with Capital Group’s SMALLCAP World Fund. The placement is equivalent to approximately 5.3% of Cosmo’s outstanding shares, subject to regulatory disclosure. The placement was executed using existing treasury shares and therefore does not...
About this update from Cosmo Pharmaceuticals Nv
[{"type":"text","content":"Dublin, Ireland--(Newsfile Corp. - February 3, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the successful completion of a private placement of 937,086 treasury shares. The shares were placed with Capital Group’s SMALLCAP World Fund.","length":272,"tagName":"p"},{"type":"text","content":"The placement is equivalent to approximately 5.3% of Cosmo’s outstanding shares, subject to regulatory disclosure. The placement was executed using existing treasury shares and therefore does not result in dilution for existing shareholders.","length":241,"tagName":"p"},{"type":"text","content":"This investment represents one of the most significant institutional placements in Cosmo’s recent history and marks a major milestone in the Company’s ongoing transformation into a focused, innovation driven healthcare leader.","length":226,"tagName":"p"},{"type":"text","content":"The transaction further strengthens Cosmo’s shareholder base, enhances financial flexibility, and supports continued investment behind the Company’s strategic growth priorities across MedTech AI, dermatology, gastroenterology, and CDMO.","length":236,"tagName":"p"},{"type":"text","content":"Giovanni Di Napoli, Chief Executive Officer of Cosmo Pharmaceuticals, commented: “We see this transaction as an important step in accelerating our journey and delivering long term value for all shareholders. The investment was enabled by the progress we have made, the clarity of our Vision 2030 strategy, and our ambition to build a global healthcare innovation company at the intersection of therapeutics, digital platforms, and AI enabled MedTech.”","length":451,"tagName":"p"},{"type":"text","content":"Svetlana Sigalova, Chief Financial Officer of Cosmo Pharmaceuticals, added: “This transaction reflects a highly strategic and disciplined use of treasury shares. It reinforces the strength of our financial position and supports our long-term capital allocation priorities as we continue to invest behind innovation, growth, and strategic execution.”","length":349,"tagName":"p"},{"type":"text","content":"The transaction was conducted as a private placement with a single institutional investor. The shares are fully fungible with existing listed shares and rank pari passu in all respects. In accordance with applicable regulations, Cosmo will be filing the relev...